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Summary
Background Genome-wide association studies (GWAS) for Parkinson’s disease have linked two loci (MAPT and 
SNCA) to risk of Parkinson’s disease. We aimed to identify novel risk loci for Parkinson’s disease. 
Methods We did a meta-analysis of datasets from ﬁ ve Parkinson’s disease GWAS from the USA and Europe to identify 
loci associated with Parkinson’s disease (discovery phase). We then did replication analyses of signiﬁ cantly associated 
loci in an independent sample series. Estimates of population-attributable risk were calculated from estimates from 
the discovery and replication phases combined, and risk-proﬁ le estimates for loci identiﬁ ed in the discovery phase 
were calculated.
Findings The discovery phase consisted of 5333 case and 12 019 control samples, with genotyped and imputed data 
at 7 689 524 SNPs. The replication phase consisted of 7053 case and 9007 control samples. We identiﬁ ed 11 loci 
that surpassed the threshold for genome-wide signiﬁ cance (p<5×10–⁸). Six were previously identiﬁ ed loci (MAPT, 
SNCA, HLA-DRB5, BST1, GAK and LRRK2) and ﬁ ve were newly identiﬁ ed loci (ACMSD, STK39, MCCC1/LAMP3, 
SYT11, and CCDC62/HIP1R). The combined population-attributable risk was 60·3% (95% CI 43·7–69·3). In the 
risk-proﬁ le analysis, the odds ratio in the highest quintile of disease risk was 2·51 (95% CI 2·23–2·83) compared 
with 1·00 in the lowest quintile of disease risk.
Interpretation These data provide an insight into the genetics of Parkinson’s disease and the molecular cause of the 
disease and could provide future targets for therapies.
Funding Wellcome Trust, National Institute on Aging, and US Department of Defense. 
Introduction
Parkinson’s disease was long thought to be a non-genetic 
disease. Recent advances in genotyping have enabled 
large-scale assessment of genetic risk factors associated 
with Parkinson’s disease. MAPT and SNCA1–5 have 
consistently shown associations in genome-wide 
association studies (GWAS). BST1, LRRK2, GAK, and 
HLA-DRB51–3,5–7 have been implicated in some studies but 
these associations have not been deﬁ nitively conﬁ rmed.
Although an exciting next step in the genetic study of 
human disease will be the use of exome or genome 
sequencing in adequately powered large-scale population-
based studies, this method is cost prohibitive at present.8 
A compromise between array-based and sequence-based 
methods is the use of freely available sequence-based 
resources from the 1000 Genomes Project, which allows 
imputation of a large number of variants into existing 
genotyping studies.
We did a meta-analysis of Parkinson’s disease GWAS 
to investigate the associations of previously identiﬁ ed 
loci and identify novel risk loci for Parkinson’s disease. 
Methods
Study design
Investigators representing four published GWAS1–3,9 
formed a consortium with the predetermined goal to 
discover new loci associated with Parkinson’s disease by 
a prospective meta-analysis of imputed sequence variants 
(discovery stage). We identiﬁ ed one additional dataset 
from the database of genotypes and phenotypes.5,10 A 
secondary requirement for inclusion of a dataset in this 
study was the ability to use custom-built ImmunoChip 
arrays to do replication analyses in independent sample 
series (replication stage). The ﬁ ve included datasets were 
from the USA National Institute on Aging, UK, Germany, 
France, and the USA database of genotypes and 
phenotypes.1–3,5,9,11
We aimed to assess the biological consequences of risk 
variants identiﬁ ed in our study by examining the 
association between these alleles and both gene 
expression and DNA methylation. Our primary interest 
in these single nucleotide polymorphism (SNP)-based 
analyses was to investigate every locus associated with 
Parkinson’s disease and to test whether the disease-
related SNPs were associated with DNA methylation or 
gene expression levels. Further, we wanted to test whether 
the most strongly disease-associated SNPs were also the 
most strongly associated quantitative trait locus SNPs.
Data imputation and statistical analysis
After individual sample collection and study-speciﬁ c 
quality control (webappendix pp 1–7), we used a Markov 
For the 1000 Genomes Project 
see http://www.1000genomes.
org/
See Online for webappendix
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Chain based haplotyper (MACH; version 1.0.16) on every 
dataset to impute genotypes for all participants of European 
ancestry with haplotypes derived from initial low coverage 
sequencing of 112 European ancestry samples in the 
1000 Genomes Project (as of August, 2009).12,13 For all 
datasets, data were imputed by a two-stage design. The 
ﬁ rst stage generated error and crossover maps as parameter 
estimates for imputation on a random subset of 
200 samples per study over 100 iterations of the initial 
statistical model. We used these parameter estimates to 
generate maximum likelihood estimates of allele numbers 
per SNP on the basis of reference haplotypes for the 
datasets during the second stage of the imputation. SNPs 
with RSQR quality estimates of less than 0·30 as indicated 
by MACH were excluded from analyses of the datasets, 
because imputed genotypes below this threshold are 
probably of poor quality.
We did genome-wide dataset analyses at every site with 
MACH2DAT.12 We used non-integer allele numbers as a 
primary predictor of Parkinson’s disease in logistic 
regression models to account for imputation uncertainty. 
Webappendix pp 1–7 shows speciﬁ c details of analyses of 
the datasets. Summary statistics from genome-wide 
association analyses of every dataset were included in the 
meta-analyses. For every dataset, we used basic covariates 
of component vectors 1 and 2 from either principal 
components or multidimensional scaling analyses of the 
case-control cohorts to identify random genomic 
diﬀ erences between genotyped data from cases and 
controls in the discovery phase, which were used to 
adjust statistical models for covariates accounting for 
possible population substructure. This adjustment was 
not done in analyses of the UK dataset in the discovery 
phase of analyses.
For the replication step, we included the SNPs that 
passed genome-wide signiﬁ cance (ﬁ xed eﬀ ects p<1×10–⁵) 
and quality control on a custom ImmunoChip array 
(Illumina, San Diego, CA, USA) in collaboration with the 
Sanger Institute (Hinxton, UK). Additionally, we analysed 
two GWAS (from the Netherlands and Iceland) after the 
meta-analysis and included these in the replication stage 
by the same imputation procedure. These data were 
provided by consortium members who provided the 
GWAS data after the initial discovery phase. We included 
a quality control step in the replication analyses that 
removed SNPs with inconsistent results across the 
datasets (I²>75%).14,15 Webappendix pp 4–8 shows detailed 
descriptions of the replication analyses that were done in 
the ﬁ ve ImmunoChip replication cohorts (USA, UK, 
Netherlands, Germany, and France) and two in-silico 
GWAS datasets (Iceland and Netherlands).
We did ﬁ xed-eﬀ ects inverse variance-weighted meta-
analyses with meta-analysis helper (METAL),16,17 with the 
standard errors of the β coeﬃ  cients scaled by the square 
root of study-speciﬁ c genomic inﬂ ation factor estimates 
before combining the summary statistics across datasets. 
We calculated genomic control for both individual 
datasets and the entire meta-analysis for quality control. 
Genomic control is often estimated as the deviance of 
the median test statistic distribution from the expected 
null; genomic inﬂ ation factors less than 1·05 are the 
general standard in GWAS.18 We used ﬁ xed-eﬀ ects meta-
analyses as the primary method of discovery and R 
(version 2.11) to do a secondary random-eﬀ ects meta-
analysis for every SNP.19 This second analysis is useful to 
estimate the possible eﬀ ect of study heterogeneity on 
results and to qualitatively infer the eﬀ ect of study 
heterogeneity on replication success and generalis-
ability for similar sample series. We calculated χ² tests 
for heterogeneity (Cochran’s Q) with METAL and we 
generated I² estimates with R. Meta-analyses and 
estimates of study heterogeneity were re-run with PLINK 
as a quality control measure.
We calculated risk-proﬁ le estimates on the basis of 
cumulative load of risk alleles for loci identiﬁ ed in the 
discovery phase, weighted by the discovery phase eﬀ ect 
estimates (logodds ratio). This proﬁ le model was applied to the 
ImmunoChip genotyped replication cohorts, and the 
eﬀ ects were combined across cohorts by inverse variance 
weighting.
Population-attributable risk was estimated for the 
speciﬁ c genetic contribution to disease of the risk loci 
Cases Controls Genome-wide association study
Sample size Women (%) Mean age at 
onset (years 
[SD])
Sample size Women (%) Mean age at 
examination 
(years [SD])
Number of 
successfully 
genotyped SNPs
Number of 
successfully 
imputed SNPs
Covariates Genomic 
inﬂ ation factor 
(λ)
USA–NIA 971 40·5% 55·9 (15·1) 3034 52·8% 62 (15·6) 463 187 7 590 773 Population structure* 1·043
UK 1705 43·3% 65·8 (10·8) 5200 49·5% NA 598 821 7 678 643 None 1·048
Germany 742 39·8% 56 (11·6) 944 48·0% NA 463 187 7 589 890 Population structure* 1·029
France 1039 41·2% 48·9 (12·8) 1984 33·0% 73·7 (5·4) 493 081 7 340 040 Population structure* 1·029
USA–dbGAP 876 40·4% 61·5 (9·2) 857 60·2% NA 334 513 7 482 040 Population structure* 1·023
Meta-analysis 5333 .. .. 12 019 .. .. 547 951 7 689 524† Genomic control‡ 1·042
NIA=National Institute on Aging. NA=not available. dbGAP=database of genotypes and phenotypes. *Adjusted for component vectors 1 and 2 from multidimensional scaling analyses of the study population. 
†Passed quality control in at least two of the included datasets; ‡Summary statistics scaled by study-speciﬁ c genomic inﬂ ation factors before meta-analysis.
Table 1: Dataset characteristics
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identiﬁ ed. In broad terms, it estimates the decrease in 
cases of a particular disease within a population that 
would occur if the risk factor were removed from that 
population. Eﬀ ect sizes and minor allele frequencies 
were calculated from joint estimates from the discovery 
and replication phases combined, to lessen the 
overestimation caused by the so-called winner’s curse—a 
form of ascertainment bias that often occurs in two-stage 
GWAS wherein natural genetic variation contributes to a 
slight overestimation of eﬀ ect sizes in the discovery 
phase.20 Joint estimates were also used because of their 
large sample size, which should generate more accurate 
eﬀ ect estimates.
DNA methylation values at sites close to the risk 
variants and the expression of genes within the risk loci 
were treated as quantitative traits, and we assessed 
whether the alleles of SNPs across the risk loci were 
associated with either, denoting a quantitative trait locus. 
Webappendix pp 10–13 and a previous study21 provide 
more detail about the methods used to map quantitative 
trait loci. Brieﬂ y, we used dense genotype data generated 
in up to 350 people who had donated brain tissue and 
were neurologically healthy at the time of death. DNA 
methylation and transcript expression were assessed in 
frozen tissue from both frontal cortex and cerebellum 
samples of every brain. We tested the association between 
any typed polymorphism and any assayed DNA 
methylation site or transcript. All SNPs within 1 mb from 
the SNPs with the smallest p values per locus with ﬁ xed-
eﬀ ects p values less than 1×10–⁵ were investigated as 
candidate loci that aﬀ ect the expression and methylation 
values of proximal mRNA transcript probes and CpG 
methylation sites. With the minor allele as a reference for 
directionality, we used linear models to quantify the 
relation between quantitative trait loci and risk eﬀ ect for 
all the loci that contained signiﬁ cant quantitative trait 
locus associations. We used linkage-adjusted Bonferroni 
correction for signiﬁ cance (webappendix pp 11–13).
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All members of the writing group 
had full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
The discovery phase included 5333 case and 12 019 control 
samples, with genotyped and imputed data at 
7 689 524 SNPs (table 1; ﬁ gure 1). 7053 case and 
9007 control samples were included in analyses in the 
replication stage. Results of tests across the software 
packages METAL, R, and PLINK diﬀ ered only slightly 
(data not shown). 
We identiﬁ ed 11 loci that surpassed the threshold for 
genome-wide signiﬁ cance (p<5×10–⁸; table 2).18 One locus 
on chromosome 17 from 18 601 523 to 18 602 998 bp that 
contained six SNPs associated with Parkinson’s disease 
in the UK cohort was not included because p values were 
not less than 0·1 in any other cohort and I² was greater 
than 75%. For simplicity, we have focussed only on the 
most signiﬁ cant SNP per locus that met these criteria, 
and its nearest gene or genes. However, we do recognise 
that the most proximal gene is not necessarily the gene 
functionally aﬀ ected by risk alleles and that GWAS 
identify loci rather than speciﬁ c genes. Webappendix 
pp 15–31 provides more detailed results for every region.
We conﬁ rmed the Parkinson’s disease associations at the 
SNCA and MAPT loci1–5 and at BST1, LRRK2, GAK, and 
HLA-DRB5 (table 2).1,–3,5–7 Additionally, we detected evidence 
of associations at ﬁ ve new loci (the closest gene to the top 
SNP at every loci is ACMSD, STK39, MCCC1/LAMP3, 
SYT11, and CCDC62/HIP1R). However, two of these loci 
(ACMSD and CCDC62/HIP1R) showed moderate evidence 
of heterogeneity across populations. Webappendix 
pp 7–8 provides further details about the replication phase 
of analysis. All ﬁ ve novel loci passed a Bonferroni threshold 
of p<0·0045 (correcting for the 11 SNPs tested in the 
replication phase) for association in the replication phase.
The SNP at the SYT11 locus is about 650 kb from the 
known Parkinson’s disease risk factor gene GBA and its 
pseudogene, in a region of the genome with low 
recombination.22 To test whether this proximity might 
contribute to the possible co-segregation of risk alleles at 
the SYT11 locus and GBA risk mutations we analysed 
data from a subset of patients with Parkinson’s disease 
Figure 1: Manhattan plot of Parkinson’s disease associations for all SNPs in the discovery phase
p values from ﬁ xed-eﬀ ects meta-analysis for 7 689 524 SNPs successfully imputed or genotyped in at least two individual datasets. Genomic inﬂ ation factor=1·035. Red points=SNPs with p<5×10⁸. 
Orange points=SNPs with p values ranging from less than 1×10⁵ to 5×10⁸. Regions containing red points were followed up in replication analyses. SNP=single nucleotide polymorphism.
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who were included in the discovery phase analysis and 
who were from the USA, France, and Germany, in whom 
carriers of the GBA mutation have been identiﬁ ed. The 
results of this analysis suggested that the signal at the 
SYT11 locus is independent of GBA mutations 
(webappendix pp 9–10 and pp 32–33). Similarly, we did 
an analysis that controlled for the known common 
LRRK2 mutation G2019S in the replication phase, and 
showed that the association detected in the meta-analysis 
close to LRRK2 might be caused by variation independent 
of this mutation (webappendix pp 9–10 and pp 32–33).
Table 2 shows the combined population-attributable 
risk estimates. The combined estimate across all 
11 identiﬁ ed loci was 60·3% (95% CI 43·7–69·3). For 
the MAPT and SNCA loci alone it was 25·6% 
(18·7–28·9), which was higher than the previous 
estimate of about 20%.2 The additional loci identiﬁ ed in 
this study (ACMSD, STK39, MCCC1/LAMP3, and 
CCDC62/HIP1R) had a combined estimate of 46·7% 
(30·7–56·8).
The odds ratio was 2·5 times higher in the highest 
quintile of disease risk than in the lowest quintile of 
disease risk (table 3). The c index from receiver operator 
curves in the pooled cohorts was 0·63.
We identiﬁ ed quantitative trait associations at 
18 969 SNPs spread across ﬁ ve of the identiﬁ ed 
Parkinson’s disease risk loci (summarised in ﬁ gure 2, 
with complete results available from the authors upon 
request). The MAPT locus had many such associations, 
with 95·9% of all associations detected across all tissues 
and arrays in this region. For the MAPT locus, risk 
estimates were positively associated with quantitative 
trait locus eﬀ ects, leading to increased gene expression 
(cerebellum r² 0·1366; frontal cortex r² 0·8042; both 
tissues p<2×10–¹⁶). We noted the opposite eﬀ ect in the 
methylation quantitative trait loci at MAPT, with minor 
C Position 
(bp)
MAF in 
discovery 
phase
Minor/
major 
alleles
Candidate 
gene
Discovery phase Replication phase Combined PAR 
estimate (95% CI)
OR (SE) per 
minor allele 
dose
Fixed 
eﬀ ects 
p value
Random 
eﬀ ects 
p value
I2 index 
(%)
I2 
p value
OR (SE) per 
minor allele 
dose
Fixed 
eﬀ ects 
p value
chr1:154105678 1 154 105 678 0·02 T/C SYT11 1·67 (0·09) 1·02×10⁸ 5·70×10⁹ 0·00% 0·77 1·44 (0·08) 1·18×10⁶ 1·21% (0·34–1·47)
rs6710823 2 135 308 851 0·19 A/G ACMSD 1·38 (0·05) 1·35×10⁹ 1·61×10⁵ 48·26% 0·11 1·07 (0·02) 0·003161 4·05% (1·66–6·82)
rs2102808 2 168 825 271 0·13 T/G STK39 1·28 (0·04) 3·31×10¹¹ 1·54×10¹¹ 0·00% 0·72 1·12 (0·04) 0·001639 2·29% (1·11–2·98)
rs11711441 3 184 303 969 0·14 A/G MCCC1/LAMP3 0·82 (0·04) 2·10×10⁸ 1·17×10⁸ 0·00% 0·97 0·87 (0·03) 6·92×10⁵ 13·71% (9·05–17·70)
chr4:911311 4 911 311 0·28 C/G GAK 1·21 (0·03) 1·80×10¹² 2·96×10⁷ 51·58% 0·09 1·14 (0·02) 7·46×10⁸ 4·87% (2·68–6·38)
rs11724635 4 15 346 199 0·45 C/A BST1 0·87 (0·03) 1·85×10⁸ 0·001407 74·77% 4·1×10³ 0·87 (0·02) 2·43×10⁹ 7·82% (5·30–9·47)
rs356219 4 90 856 624 0·39 G/A SNCA 1·30 (0·03) 7·90×10²⁶ 1·11×10²⁶ 0·00% 0·58 1·27 (0·02) 4·23×10²³ 9·71% (6·68–10·27)
chr6:32588205 6 32 588 205 0·15 G/A HLA-DRB5 0·70 (0·06) 2·58×10⁸ 1·44×10⁸ 0·00% 0·88 0·80 (0·04) 9·30×10⁸ 17·68% (11·04–23·00)
rs1491942 12 38 907 075 0·21 G/C LRRK2 1·19 (0·03) 3·23×10⁸ 5·24×10⁶ 35·52% 0·20 1·30 (0·05) 1·06×10⁸ 2·09% (1·00–2·50)
rs12817488 12 121 862 247 0·46 A/G CCDC62/HIP1R 1·16 (0·03) 4·43×10⁹ 2·99×10⁶ 34·97% 0·20 1·13 (0·03) 9·06×10⁷ 5·56% (3·20–7·37)
rs2942168 17 41 070 633 0·22 A/G MAPT 0·76 (0·03) 1·62×10¹⁸ 3·91×10¹⁹ 0·00% 0·74 0·80 (0·03) 1·37×10¹³ 17·57% (12·92–20·78)
Only loci with p<5×10–8 in the meta-analysis are shown. The SNP with the smallest p value per locus on the basis of a ﬁ xed eﬀ ects meta-analysis is shown. Webappendix pp 15–31 provide additional details for the 
associated loci described above. An expanded version of this table that shows all p values less than 1×10–5 from the discovery phase of analyses is available upon request. C=chromosome. MAF=minor allele 
frequency. OR=odds ratio. PAR=population-attributable risk. I2 index=I2 index of heterogeneity. I2 p value=heterogeneity p value.
Table 2: Summary of signiﬁ cant loci
p value AUC Risk quintile OR (95%CI)
First 
(reference 
group)
Second Third Fourth Fifth
USA <2×10¹⁶ 0·584 1·00 1·49 (1·25–1·78) 1·67 (1·40–2·00) 1·90 (1·59–2·27) 2·25 (1·88–2·70)
UK <2×10¹⁶ 0·631 1·00 1·63 (1·27–2·08) 2·26 (1·77–2·88) 2·65 (2·09–3·38) 3·30 (2·60–4·21)
Germany 1·44×10⁸ 0·69 1·00 1·16 (0·86–1·57) 1·55 (1·14–2·11) 1·68 (1·23–2·29) 2·06 (1·51–2·82)
France 6·15×10⁹ 0·644 1·00 1·24 (0·72–2·16) 2·13 (1·26–3·66) 2·84 (1·68–4·88) 4·31 (2·51–7·55)
Netherlands 8·34×10⁴ 0·576 1·00 1·21 (0·74–2·00) 1·12 (0·68–1·84) 1·50 (0·93–2·42) 1·89 (1·17–3·07)
Combined <2×10¹⁶ 0·63 1·00 1·43 (1·27–1·62) 1·77(1·55–1·99) 2·03 (1·80–2·32) 2·51 (2·23–2·83)
Cases (%) .. .. 886 (39·00%) 1069 (47·13%) 1185 (52·16%) 1268 (55·93%) 1394 (61·17%)
Combined analyses showed low heterogeneity of eﬀ ect (Cochran’s Q p>0·01). AUC=area under curve, indicated by the c index from receiver operator curves. OR=odds ratio.
Table 3: Summary of risk-proﬁ le analyses
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alleles associated with increased risk and with decreased 
methylation (cerebellum r² 0·9268, p <2×10–¹⁶; frontal 
cortex r² 0·4667, p=3·68×10–⁶). The MAPT locus showed 
associations for multiple probes within MAPT and 
probes within proximal genes, including ARL17A and 
PLEKHM1. Methylation quantitative trait loci in the 
MAPT region included probes within KIAA1267, 
LRRC37A, and NSF.
Two SNPs in the ACMSD locus showed substantial 
associations, with expression levels in cerebellar tissues 
denoted by a proximal expression probe against the 
transcript MCM6, whose transcription start site is more 
than 750 kb from either associated SNP; the minor 
alleles at this pair of SNPs are associated with increased 
risk of Parkinson’s disease and decreased gene 
expression. In samples from the frontal cortex, DNA 
methylation values at one CpG site within FGFRL1 were 
associated with 27 proximal SNPs in the GAK region 
(>20 kb from the nearest SNP associated with Parkinson’s 
disease), and all eﬀ ect estimates suggested risk of 
Parkinson’s disease and increased methylation (r² 0·9897, 
p<2×10–¹⁶).
The HLA-DRB5 region contained 729 signiﬁ cant 
quantitative trait locus associations in the frontal and 
cerebellar tissue samples. For HLA-DRB5, we recorded 
an overall result similar to that identiﬁ ed at MAPT, with 
minor alleles associated with risk eﬀ ects and with 
decreased DNA methylation (cerebellum r² 0·4037, 
p=9·67×10–⁵; frontal cortex r² 0·4977, p<2×10–¹⁶).
In addition to probes within HLA-DRB5, methylation 
quantitative trait locus associations were detected within 
probes tagging CpG sites in BTNL2, HLA-DQB2, and 
SLC44A4. One CpG probe in the cerebellum samples was 
associated with 18 SNPs in the CCDC62/HIP1R region. 
We noted a relation between risk alleles and DNA 
methylation at a CpG site within GPR109B, for which 
increased risk estimates were closely associated with 
more negative methylation eﬀ ects (cerebellum r² 0·4977, 
p<2×10–¹⁶).
Both the LRRK2 and SNCA genes play a part in 
Parkinson’s disease; thus, we examined these loci further 
for potential quantitative trait loci. Detection of LRRK2 
with the array-based method showed expression that was 
too low to do an accurate analysis. However, we identiﬁ ed 
quantitative trait loci at the SNCA locus, where risk 
alleles were associated with increased SNCA expression. 
Although evidence suggests a link between SNCA 
expression and disease risk,23 the level of signiﬁ cance for 
this locus was not signiﬁ cant (p=1×10–⁴) with the threshold 
for signiﬁ cance that we set (p<3·55×10–⁵).
Discussion
SNCA, MAPT, and HLA-DRB5 have been conﬁ rmed as 
risk loci for Parkinson’s disease by previous GWAS1–7,9 
and by our meta-analysis. We have also shown that, 
although previous GWAS were individually under-
powered to prove the associations between the BST1, 
LRRK2, and GAK loci and Parkinson’s disease, our meta-
analysis and replication analysis identiﬁ ed an association 
at these loci (panel).1–3,5,6,9
GWAS investigate loci that often contain several genes 
and we should be mindful not to ascribe disease risk to 
any one gene within this locus in the absence of further 
biological evidence. However, the novel loci detected 
include biologically plausible candidate for Parkinson’s 
Figure 2: Summary of quantitative trait locus analyses
The left column shows the concordance between meta-analysis eﬀ ect estimates and QTL eﬀ ect estimates for SNPs 
at ﬁ ve loci with signiﬁ cant QTL associations. The right column shows the position of signiﬁ cantly associated SNPs 
from the QTL analyses within every region of interest. Orange circles=expression assayed in the frontal cortex. Red 
circles=expression assayed in the cerebellum. Purple circles=methylation assayed in the frontal cortex. Blue 
circles=methylation in the cerebellum. Grey circles=associations tested but that did not pass the Bonferroni 
correction threshold for signiﬁ cance (only plotted in the bottom row). QTL=quantitative trait locus. SNP=single 
nucleotide polymorphism.
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disease risk. ACMSD is associated with picolinic and 
quinolinic acid homoeostasis and is a possible therapeutic 
target for several disorders that aﬀ ect the CNS.24 The 
locus identiﬁ ed near STK39 has been associated with 
autism, hypertension, and inﬂ ammatory status,25–27 
although there have been no reports of this locus 
contributing to neurodegenerative phenotypes. The 
LAMP3 locus might partly cause modulation of neuronal 
and neurosecretory function in PC12 cell lines.28 
HLA-DRB5 is associated with multiple sclerosis, 
immunocompetence, and histocompatibility.29–31 The 
association with Parkinson’s disease at HLA-DRB5 
supports the theory that inﬂ ammatory factors are 
associated with the pathogenesis of Parkinson’s disease.32 
The protein product of HIP1R is functionally involved in 
intrinsic cell-death pathways and interacted with 
huntingtin to modulate polyglutamine-induced neuronal 
dysfunction in transgenic worm and mouse models.33 
Finally, the association detected at the SYT11 locus 
includes a gene that has been investigated previously in a 
negative mutation screening study in 393 patients with 
familial or sporadic Parkinson’s disease34 and in a cell 
biology study that showed an interaction between the 
protein products of SYT11 and PARK2 in patients with 
Parkinson’s disease.35
The association between genetic variability at the 
LRRK2 locus and Parkinson’s disease is mechanistically 
interesting because data suggest that this association is 
a result of variability outside the common G2019S 
mutation, which raises the possibility that splicing or 
expression of wild-type LRRK2 might be pathologically 
important. If this suggestion is correct, the role of 
LRRK2 in Parkinson’s disease might relate to an 
exaggeration of its normal function rather than some 
gain of abnormal function.
Understanding of the pathobiologically relevant eﬀ ect 
of the identiﬁ ed risk variants in Parkinson’s disease is 
challenging. However, we associated changes in 
expression and DNA methylation with risk alleles at ﬁ ve 
of the identiﬁ ed loci. This work has many caveats, not 
least of which is that it is associative and does not imply 
causality. However, these data do serve as a launching 
point for further investigation into the biological basis of 
Parkinson’s disease.
The absence of predictive capacity in the risk-proﬁ le 
estimates suggests that common genetic variability at 
these loci, the small risk estimates per locus in this meta-
analysis (and GWAS-based studies in general), and the 
inability to include putative functional variants per locus, 
do not allow clinically relevant predictive power to be 
quantiﬁ ed. Additionally, no environmental factors were 
included in risk proﬁ ling or population-attributable risk 
estimates, which might have led to some overestimation 
of the genetic risk of Parkinson’s disease, because its 
cause is probably not entirely genetic.
Assumptions are unavoidable when modelling 
population-attributable risk with data from GWAS. Thus, 
we have probably overestimated the genetic component 
of Parkinson’s disease risk on the basis of these loci alone 
because bias inherent in using a case-control study will 
slightly skew the frequency of risk alleles higher. 
However, this calculation did allow us to rank the 
contribution of every locus to the genetic cause of 
Parkinson’s disease, and to estimate the possible decrease 
in the future incidence of Parkinson’s disease achieved 
by preventative treatments targeted at genetic causes. 
Risk-proﬁ le modelling provides a conservative estimate 
of genetic risk and has moderate predictive power. The 
identiﬁ cation of additional common and rare risk variants 
for Parkinson’s disease will probably revise our estimate 
of the genetic component of disease upward.
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Interpretation
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identiﬁ ed ﬁ ve new loci. This study provides evidence that 
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